PTC takes a chance on Sangamo’s Fabry disease gene therapy

PTC takes a chance on Sangamo’s Fabry disease gene therapy →

Wall Street analysts view the deal as a risky, high-reward bet on a treatment that’s nearing a possible regulatory approval and could be superior to existing medications.